Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 16/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26608644 | 0.91 | CRBN (0.58) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL26609402 | 0.90 | CRBN (0.54) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL26608990 | 0.89 | CRBN (0.65) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL26610218 | 0.88 | CRBN (0.63) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL26609761 | 0.88 | CRBN (0.52) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL26609480 | 0.88 | CRBN (0.54) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL26608592 | 0.88 | IKZF2 (0.54) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL26610209 | 0.88 | CRBN (0.55) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL26609340 | 0.86 | IKZF2 (0.56) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL26609757 | 0.86 | CRBN (0.50) | CRBNIKZF3DDB1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | CRBN 2723/4885IKZF3 973/4885DDB1 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.